Richard Markus

Richard Markus

Company: Dantari

Job title: Chief Executive Officer


Beyond ADCs – Next-Generation Targeted Nanoparticle Drug Conjugates (T-NDCs) 11:10 am

Outlining the advantages of T-NDCs including ~10x DAR for both targeted and bystander-mediated killing, and allows for the use of moderate potent payloads and can avoid highly toxic agents Analyzing how nanoparticle delivery is optimized for pharmacokinetic and biodistribution with broad therapeutic index Developing T-NDCs allows flexibility of binder (mAb, FAB, peptide), and has the…Read more

day: Scientific Program Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.